| Identification | Back Directory | [Name]
Lobradimil | [CAS]
159768-75-9 | [Synonyms]
RMP 7
DRG0182
DRG-0182
DRG 0182
ALK-01-040
Labradimil
Lobradimil
Receptor-mediated permeabiliser-7
LabradiMil, LabrodiMil, RMP-7, LobradiMil
(Hyp3,b-(2-thienyl)-Ala5,Tyr(Me)8-()-Arg9)-Bradykinin
(Hyp3,beta-(2-thienyl)-Ala5,Tyr(Me)8-(R)-Arg9)-Bradykinin
(Hyp3,β-(2-thienyl)-Ala5,Tyr(Me)8-psi(CH2NH)Arg9)-Bradykinin
(Hyp3,β-(2-thienyl)-Ala5,Tyr(Me)8-psi(CH2NH)Arg9)-Bradykinin
H-Arg-Pro-Hyp-Gly-b-(2-thienyl)-Ala-Ser-Pro-Tyr(Me)-()-Arg-OH
(Hyp3,β-(2-thienyl)-Ala5,Tyr(Me)8-()-Arg9)-Bradykinin Lobradimil
(Hyp3,β-(2-thienyl)-Ala5,Tyr(Me)8-(?)-Arg9)-Bradykinin Lobradimil
H-Arg-Pro-Hyp-Gly-b-(2-thienyl)-Ala-Ser-Pro-Tyr(Me)-psi(CH2NH)Arg-OH
(Hyp3,b-(2-thienyl)-Ala5,Tyr(Me)8-psi(CH2NH)Arg9)-Bradykinin (H-6578.0005)
L-Arginine, L-arginyl-L-prolyl-(4R)-4-hydroxy-L-prolylglycyl-3-(2-thienyl)-L-alanyl-L-seryl-L-prolyl-O-methyl-L-tyrosyl-ψ(CH2-NH)- | [Molecular Formula]
C49H75N15O12S | [MDL Number]
MFCD09837750 | [MOL File]
159768-75-9.mol | [Molecular Weight]
1098.29 |
| Hazard Information | Back Directory | [Uses]
Adjuvant;
receptor-mediated permeabiliser. | [in vivo]
Lobradimil (2.5-mg/kg bolus plus 10 mg/kg/h for 90 minutes) increases brain tumor permeability and shows hypotensive effects in RG2 glioma cells-implanted rats[2].
| Animal Model: | RG2 glioma cells-implanted rats[2] | | Dosage: | 1.5-18 μg/kg | | Administration: | i.v. infusion, 0.05 mL/min for 15min | | Result: | Increased Carboplatin (HY-17393) uptake (up to 80%) into brain tumors in a dose-dependent manner. |
| [IC 50]
Bradykinin B2 Receptor (B2R): 0.54 nM (Ki) |
|
| Company Name: |
BOC Sciences
|
| Tel: |
1-631-485-4226; 16314854226 |
| Website: |
https://www.bocsci.com |
|